Organization: Health Canada
Year: 2024
Month: August
Request Number: A-2023-001300
Request Summary: Correspondence relating to any abbreviated new drug submission (ANDS) filed since January 1, 2023 where the medicinal ingredient is estradiol alone and the product’s indications include the treatment of postmenopausal moderate to severe dyspareunia.
Disposition: Disclosed in part
Number of pages: 75